

# When is immunohistochemistry useful in adult medical liver disease?

Chris Bellamy  
Edinburgh


# Plan

- examples
- 51 UK pathologists
  - -50 bx      20%
  - -100 bx     27%
  - -200 bx     27%
  - >200 bx    26%


# paraffin sections: added value

- immunohistochemistry
  - antigen retrieval
  - enhanced detection
    - polymer (e.g. Envision dextrane chain)
- *in situ* hybridisation
  - oligonucleotide probes
  - peptide nucleic acid probes
- patch size - “clonality”
  - X-chromosome methylation (HUMARA)
- proteomics
  - comparative mass spectrometry
- expression microarrays
  - Exon chips

## Local Ab repertoire



## Requesting ihc





# immunohistochemistry





- **Anatomy**
  - **decorate**: arterioles, bile ducts, ductules, “capillarisation”, stellate cells, lymphatics, matrix
- **Foreign proteins**
  - **extrinsic**: infections
  - **intrinsic**: metastasis, inflammation, amyloid, Ab
- **Altered expression**
  - **homeostasis**: cell cycle, stress response, apoptosis
  - **disorganised**: storage disorder, Mallory
  - **illicit**: neoplasia

# Anatomy


podoplanin








### ihc utility to diagnose ductopenia




## Bile duct staining




# Bile ducts: CK7, CK19



- also
  - canal of Hering cholangiocytes, “progenitors”
  - bile ductules
- in disease
  - ductular reaction radiating from coH
  - intermediate cells (6-40 $\mu$ ) (CK7) (adj to ductules)
  - cholate stasis in periportal hepatocytes (CK7)
  - cholestasis in chronic PBC (CK7) [Yabushita K, 2001]




CK7




CK19




CK7



Paracetamol overdose 60 hours




Paracetamol overdose



Paracetamol overdose


**MIB1**



Paracetamol overdose



**CK7**

**CK19**




Allograft fibrosing cholestatic hepatitis C

CK7



PBC cirrhosis: CK7




# Infections

- Hepatitis B
- CMV
- EBV
- Hepatitis D
- Hepatitis C
- Hepatitis A
- Others

– Hepatitis E [ZhaiQ,1991&1994]





# Utility of ihc to diagnose/Mx infections





# Hepatitis B

- nucleocapsid core protein (cAg)
  - viral replication
  - nuclear (+/- cytoplasmic)
- envelope surface protein (sAg)
  - cytoplasmic (+/- [sub]membranous)
  - “ground glass” cells
    - ΔΔ glycogen, cyanamide, “induction”



core Ag




surface Ag



surface Ag







# Hepatitis D ihc

- European genotype I
  - acute (replicating, HBV cAg suppression)
  - chronic (less replication & HBV suppression)
  - late
- ihc: nuclear positivity
  - sanded nuclei (HDAg)
  - weak/no cytoplasmic staining
  - useful to rapidly diagnose acute coinfection

# CMV

- usually viral inclusions evident
- ihc to early Ag



# Acute adult EBV hepatitis







- EBV early RNA (EBER)
  - [SuhN, AJSPath, Sept 2007]
    - 8 patients: acute fever, J, lymphocytosis,
    - sinusoidal “beading”, portal mixed & variable interface/lobular hepatitis, venulitis, bile duct injury
    - very sparse EBER +ve lymphocytes (7/8)
    - LMP ihc negative (8/8)

# Systemic IgG<sub>4</sub> disease

- corticosteroid-sensitive multisystem nodular fibroinflammatory disease
- tissue infiltration with IgG<sub>4</sub> plasma cells
  - typically raised serum IgG<sub>4</sub>
  - pancreatitis, cholecystitis, cholangitis, Mikulicz's disease, interstitial nephritis, pneumonitis, retroperitoneal fibrosis, gastric ulcer, "PBC-like" inflammation, inflammatory pseudotumour, fevers
  - bispecific, IL-4/T<sub>H2</sub>

# Systemic IgG<sub>4</sub> disease

- wide spectrum
- discrete, intense, mass-forming/segmental
- obliterative phlebitis
- eosinophilia/plasma cells
- sclerosis
- bottom heavy-mural infiltrate (gb, cbd)



# Systemic IgG<sub>4</sub> disease

- **liver biopsy involvement: sensitive**
  - large duct obstruction
  - plasma cell-rich portal inflammation +/-interface
  - lobular hepatitis
  - perivenular cholestasis
  - periportal fibrosis





ihc: >1/hpf or >20% [UmemuraT2007]

- **consider if...**“Sjogrens”, sialadenitis, cancer-negative Whipples, wheeze, dry eyes/mouth, interstitial nephritis...

# Amyloid, MIDD



- acquired
  - AA
  - AL (lambda 3x kappa)
- hereditary
  - neuropathic
  - non-neuropathic
    - fibrinogen  $\alpha$  chain, lysozyme, apolipoprotein A1
- MIDD (light+/heavy chain)

Liver amyloid (Rheumatoid)




# $\alpha$ 1-antitrypsin deficiency

- Z mutant vs normal protein
- ihc more sensitive than PAS/D
  - missed 0 vs 5/33 adults [CalleaF,1986]
- globules >3u
  - specific but 47% of Z allele [ClausenPP1984]
- in cirrhosis with globules
  - 10% - but variety of phenotypes, some normal [IezzoniJC,1997]
- **$\alpha$ 1antichymotrypsin deficiency**
  - smaller, weaker PAS/D+, ihc available [ThomasRM2000]
- **$\Delta\Delta$**  stressed liver, congestion-associated, fibrinogen storage disease




PiMZ stressed liver (ALD)





PiZZ

Ubiquitin




Cam5.2




**Mallory bodies**

## utility of specific ihc






■ Mallory body ■ a1AT

## ihc importance in medical liver diseases




■ AIH ■ overlap ■ steatohepatitis ■ a1AT deficiency



# Requesting ihc in malignancy




## Requesting ihc in hepatocellular lesions



■ HCC vs Dysplasia ■ HCC vs Adenoma ■ Adenoma vs FNH




## Hepatocellular differentiation in malignancy





**also CD13 (RockenC2005)**


**CD10: canalicular staining**




# ihc in liver dysplasia/HCC




**Glypican-3**





- oncofoetal protein marking early HCC
- 70-90% HCC, esp in cirrhosis
- 10-50% HG dysplasia
- 0-3% LG dysplasia
- membranous, canalicular, cytoplasmic
- [ZhuHW2001, CapurroM2003, YamauchiN2005, WangXY2006, LibbrechtL2006]

# CD34 marking HCC in cirrhosis




# “capillarised” vessels in HCC, dysplasia

- CD34, CD31, BNH9
- 40% DN
- 85% HCC
- MotooY1993, RoncalliM1999, FrachonS2001

# Adenoma typing & ihc

- Bioulac-Sage P: Hepatology, 2007
- HNF1 $\alpha$  inactivation: absent L-FABP
- $\beta$ -catenin activation: glutamine synthetase/ $\beta$ -catenin
- Inflammatory/telangiectatic: SAA $\uparrow\uparrow$ ,  $\beta$ -catenin N
- $\beta$ -catenin mutated adenomas ? higher risk to be borderline or have HCC



cirrhotic nodule in PBC